-
EP2892537
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2892537
| EP2892537 - METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 21.09.2018 Database last updated on 19.07.2024 | |
| Former | Examination is in progress Status updated on 07.12.2016 | Most recent event Tooltip | 21.09.2018 | Withdrawal of application | published on 24.10.2018 [2018/43] | Applicant(s) | For all designated states Celgene Corporation 86 Morris Avenue Summit, NJ 07901 / US | [2015/29] | Inventor(s) | 01 /
GANDHI, Anita 37 Stirling Road Bernardsville, NJ 07924 / US | 02 /
DIMARTINO, Jorge 1610 Fairway Drive Belmont, CA 94002 / US | 03 /
CHOPRA, Rajesh 54 Eggers Court Summit, NJ 07901 / US | [2015/29] | Representative(s) | Jones Day Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11 80538 München / DE | [2015/29] | Application number, filing date | 13762713.9 | 09.09.2013 | WO2013US58744 | Priority number, date | US201261699170P | 10.09.2012 Original published format: US 201261699170 P | [2015/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014039960 | Date: | 13.03.2014 | Language: | EN | [2014/11] | Type: | A1 Application with search report | No.: | EP2892537 | Date: | 15.07.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.03.2014 takes the place of the publication of the European patent application. | [2015/29] | Search report(s) | International search report - published on: | EP | 13.03.2014 | Classification | IPC: | A61K31/5377, A61K31/517, A61K45/06, A61K31/445, A61K31/454, A61P35/00, A61P35/04 | [2015/29] | CPC: |
A61K31/5377 (EP,US);
A61K31/445 (EP,US);
A61K31/454 (EP,US);
A61K31/517 (EP,US);
A61K45/06 (EP,US);
A61P35/00 (EP);
A61P35/04 (EP);
A61P37/02 (EP);
A61P43/00 (EP);
| C-Set: |
A61K31/445, A61K2300/00 (US,EP);
A61K31/454, A61K2300/00 (US,EP);
A61K31/517, A61K2300/00 (US,EP);
A61K31/5377, A61K2300/00 (EP,US) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/29] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON LOKAL FORTGESCHRITTENEM BRUSTKREBS | [2015/29] | English: | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | [2015/29] | French: | MÉTHODES POUR LE TRAITEMENT DU CANCER DU SEIN LOCALEMENT AVANCÉ | [2015/29] | Entry into regional phase | 08.04.2015 | National basic fee paid | 08.04.2015 | Designation fee(s) paid | 08.04.2015 | Examination fee paid | Examination procedure | 08.04.2015 | Examination requested [2015/29] | 02.12.2015 | Amendment by applicant (claims and/or description) | 08.08.2016 | Despatch of a communication from the examining division (Time limit: M04) | 05.12.2016 | Reply to a communication from the examining division | 18.08.2017 | Despatch of a communication from the examining division (Time limit: M04) | 22.12.2017 | Reply to a communication from the examining division | 16.08.2018 | Despatch of a communication from the examining division (Time limit: M04) | 18.09.2018 | Application withdrawn by applicant [2018/43] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.08.2016 | Fees paid | Renewal fee | 28.09.2015 | Renewal fee patent year 03 | 27.09.2016 | Renewal fee patent year 04 | 27.09.2017 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AD]US2011196150 (MAN HON-WAH [US], et al) [AD] 1-28* the whole document *; | [XP]WO2012125459 (CELGENE CORP [US], et al) [XP] 1,8,14-23 * page 58, line 32 - page 59, line 4; claims 1, 33-38, 40 *; | [XP]WO2012149299 (CELGENE CORPORAITON [US], et al) [XP] 1-28 * page 65, lines 20-24; claim 1 *; | [X] - BURRIS HOWARD A 3RD ET AL, "Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.", CANCER INVESTIGATION MAY 2010, (201005), vol. 28, no. 4, ISSN 1532-4192, pages 408 - 412, XP009173331 [X] 1,3,4,14,15,23 * abstract * | [T] - Y. X. ZHU ET AL, "Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide", BLOOD, (20111103), vol. 118, no. 18, doi:10.1182/blood-2011-05-356063, ISSN 0006-4971, pages 4771 - 4779, XP055041157 [T] 25-28 DOI: http://dx.doi.org/10.1182/blood-2011-05-356063 | Examination | US7635700 | WO2014004990 | WO2014025960 | by applicant | US3536809 | US3598123 | US3845770 | US3916899 | US4008719 | US4810643 | US4999291 | US5059595 | US5073543 | US5120548 | US5134127 | US5229496 | US5354556 | US5391485 | US5393870 | US5528823 | US5580755 | US5591767 | US5639476 | US5674533 | US5733566 | WO9854170 | US6281230 | US6316471 | US6395754 | US6555554 | US2004029832 | US7091353 | US7635700 | US7709502 | US7812169 | US2011196150 | - ROITT, I.; BI-OSTOFF, J.; KALE, D., lmmunology, MOSBY, (1993), pages 17.1 - 17.12 | - CAIRNS, R.A. ET AL., NATURE REV., (2011), vol. 11, pages 85 - 95 | - KUO, H.-P., BBRC, (2009), vol. 389, page 640 | - SHACKELFORD, D. B.; SHAW, R.J., NATURE REV. CANCER, (2009), vol. 9, pages 563 - 575 | - MARDIS, E.R. ET AL., N. ENGL. J. MED., (2009), vol. 361, pages 1058 - 1066 | - PARSONS, D. W. ET AL., SCIENCE, (2008), vol. 321, pages 1807 - 1812 | - BRITO, L. G. 0., CLINICAL SCIENCE, (2011), vol. 66, page 1313 | - LI, B. D. ET AL., ONCOLOGY, (2010), vol. 79, page 3 | - STOCKDALE, Medicine, (1998), vol. 3 | - GILMAN ET AL., Goodman and Gilman's: The Pharmacological Basis of Therapeutics, MCGRAW HILL | - Burger's Medicinal Chemistry and Drug Discovery, (1995), vol. 172-178, pages 949 - 982 | - THERASSE ET AL., J. NATL. CANCER INST, (2000), vol. 92, pages 205 - 16 | - PENICHET, M.L.; MORRISON, S.L., J. IMMUNOL. METHODS, (2001), vol. 248, pages 91 - 101 | - EMENS, L.A. ET AL., CURR. OPINION MOL. THER., (2001), vol. 3, no. 1, pages 77 - 84 | - "Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines", JOURNAL OF THE NATIONAL CANCER INSTITUTE, (2000), vol. 92, no. 3, pages 205 - 216 | - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, MARCEL DEKKER, NY, NY, (1995), pages 379 - 80 | - DRUGS OF THE FUTURE, (2003), vol. 28, no. 5, pages 425 - 431 | - BOEHM, J. S.; ZHAO, J. J; YAO J. ET AL., CELL, (2007), vol. 129, pages 1065 - 1079 | - BRITO, L. G. O., CLINICAL SCIENCE, (2011), vol. 66, page 1313 |